Global Pulmonary Embolism Market Analysis (2026–2030) With Strategic Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Pulmonary Embolism Market From 2026 To 2030?

The pulmonary embolism market has experienced substantial expansion in recent years. It is projected to rise from $2.26 billion in 2025 to $2.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. Historically, this growth has been fueled by factors such as the increasing occurrence of cardiovascular and thromboembolic conditions, the enhancement of hospital emergency care provisions, the expanded use of anticoagulant drugs, a heightened understanding of pulmonary embolism indicators, and the availability of advanced diagnostic imaging solutions.

The pulmonary embolism market is anticipated to experience substantial growth in the coming years, with its size projected to reach $4.14 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period is primarily attributed to increased investments in sophisticated anticoagulant drugs, the rising adoption of catheter-based intervention techniques, the broadening scope of early diagnostic screening programs, an escalating focus on outpatient management strategies, and a growing demand for personalized cardiovascular care. Key trends foreseen in this period encompass the increased acceptance of novel anticoagulant therapies, a surge in the utilization of minimally invasive thrombectomy devices, a sharpened focus on timely and accurate diagnosis, the expansion of integrated care pathways, and an intensified emphasis on risk stratification and prevention.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What Factors Are Contributing To The Growth Of The Pulmonary Embolism Market?

The rising occurrence of cancer is projected to stimulate expansion within the pulmonary embolism market. Cancer constitutes a category of illnesses marked by the unregulated and atypical proliferation of cells in the human body. A greater incidence of cancer elevates the likelihood of blood clots, including pulmonary embolism, among individuals with cancer. Consequently, this results in a heightened need for diagnostic tools and therapeutic interventions, encompassing specialized medications. As an illustration, figures from the American Cancer Society, a US-based nonprofit cancer advocacy organization, indicated that in January 2024, cancer cases rose to 2,001,140 from 1,958,310 in 2023, representing a 2.19% increase. Hence, the expanding presence of cancer is a key factor propelling the development of the pulmonary embolism market.

How Is The Pulmonary Embolism Market Broken Down By Segment Categories?

The pulmonary embolism market covered in this report is segmented –

1) By Treatment: Medications, Mechanical Devices, Other Treatments

2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis

3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medications: Anticoagulants, Thrombolytics

2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy

3) By Other Treatments: Surgical Embolectomy, Supportive Care

What Trends Are Shaping The Future Of The Pulmonary Embolism Market?

Leading firms within the pulmonary embolism market are concentrating on creating advanced products, including the Triever16 Curve catheter and the RevCore thrombectomy catheter, to secure an edge over competitors. An example of this is the launch by Inari Medical Inc., a US-based medical device company, of both the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The innovative Triever16 Curve catheter is specifically engineered for use in peripheral thrombectomy and pulmonary embolism procedures. It offers high trackability and features a pre-formed curve to enable precise aspiration. Its distinct design also facilitates effortless connection with larger and more robust 20F or 24F catheters, while the RevCore thrombectomy catheter is intended for addressing venous in-stent thrombosis. This device operates as a mechanical thrombectomy tool, employing a nitinol basket to entrap and eliminate blood clots. Furthermore, these catheters contribute to enhancing the safety and efficacy of pulmonary embolism interventions.

Which Players Are Present In The Pulmonary Embolism Market Space?

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson And Johnson Private Limited, F Hoffmann La Roche Ltd., Merck And Co Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK plc, Abbott Laboratories, AstraZeneca plc, Medtronic plc, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd., CSL Behring GmbH, Grifols S.A., Octapharma AG, Kedrion S.p.A

Get The Full Pulmonary Embolism Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Which Region Is The Top Contributor To The Pulmonary Embolism Market By Share?

North America was the largest region in the pulmonary embolism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary embolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pulmonary Embolism Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Browse Through More Reports Similar to the Global Pulmonary Embolism Market 2026, By The Business Research Company

Psychiatrists Market

https://www.thebusinessresearchcompany.com/report/psychiatrists-market

Oncologists Market Report

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Mental Health Market Report

https://www.thebusinessresearchcompany.com/report/mental-health-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795